(44) proposed that poly ADP-ribose polymerase-1 (PARP1) could be a marker of the efficacy of immunotherapy for patients with PBRM1-mutant ccRCC, the higher expression of which suggested poorer prognosis and higher drug resistance. In our study, 46 differentially expressed GILncs between genome-unstable and genome-stable-like groups were found, among which LINC00460, AL139351.1, and AC156455.1 were validated as significant independent prognostic factors and considered for the construction of the risk model. This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.